AIM ImmunoTech Inc.
AIM · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -15.8% | 43.3% | 4.4% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 81.8% | 79.2% | 400.7% | -529.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9,699.4% | -14,219.8% | -14,091.5% | -13,544.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -10,188.2% | -14,337.6% | -13,790.8% | -14,168.1% |
| EPS Diluted | -0.31 | -0.6 | -0.44 | -0.45 |
| % Growth | 48.3% | -36.4% | 2.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |